a-rat-orthotopic-renal-transplantation-model-for-renal-allograft

A Rat Orthotopic Renal Transplantation Model for Renal Allograft Rejection

Renal allograft rejection limits the long-term survival of patients after renal transplantation. Rat orthotopic renal transplantation is an essential ...

Chongqing University Cancer Hospital

 Gastric cancer (GC) is a common malignancy throughout the world. Biomarkers for prognosis and risk evaluation of GC are rapidly discovered. We investigated the prognostic role of FLAD1, an important protein-coding gene that affects cell cycle and survival.  The expression of FLAD1 at mRNA levels in GC tumor tissues and normal tissues was mined and analyzed in Oncomine database and verified in 10 pairs of GS tissues and their adjacent normal tissues in our center by RT qPCR. The FLAD1 protein expression were detected in 106 paraffin-embedded GC tissues by immunohistochemistry (IHC). Statistical analyses were applied to evaluate the clinical significance of FLAD1. The prognostic value of FLAD1 mRNA expression was also analyzed using the Kaplan-Meier plotter (www.kmplot.com).  Statistics obtained from online database suggested FLAD1 mRNA was overexpressed in GC tissues. The results were further validated in 10 pairs of GS tissues and adjacent normal tissues in our center (p=0.021). IHC and survival analysis of GC samples from 106 patients showed FLAD1 was overexpressed in 63/106 (59.4%) patients and was associated to higher TNM stage (p=0.026). Multivariate analysis revealed FLAD1 was an independent prognostic factor for GC (p < 0.001). Furthermore, FLAD1 mRNA was associated to unfavorable overall survival (OS), first progression (FP), and post-progression survival (PPS) of GC (p<0.001).  FLAD1 in GC is overexpressed at both mRNA and protein level and could be a potential biomarker for GC prognosis.

FLAD1 is up-regulated in Gastric Cancer and is a potential prediction of prognosis.

Early detection of colorectal carcinoma (CRC) would help to identify tumors when curative treatments are available and beneficial. However, current screening methods for CRC, e.g., colonoscopy, may affect patients' compliance due to the uncomfortable, invasive and time-consuming process. In recent decades, methylation profiles of blood-based circulating tumor DNA (ctDNA) have shown promising results in the early detection of multiple tumors. Here we conducted a study to investigate the performance of ctDNA methylation markers in early detection of CRC.

Discovery and validation of methylation signatures in blood-based circulating tumor cell-free DNA in early detection of colorectal carcinoma: a case-control study.

Aberrant DNA methylation may offer opportunities in revolutionizing cancer screening and diagnosis. We sought to identify a non-invasive DNA methylation-based screening approach using cell-free DNA (cfDNA) for early detection of hepatocellular carcinoma (HCC).

Article	Year
FLAD1 is up-regulated in Gastric Cancer and is a potential prediction of prognosis. International journal of medical sciences\| PubMed ID: 32714079	2020
Discovery and validation of methylation signatures in blood-based circulating tumor cell-free DNA in early detection of colorectal carcinoma: a case-control study. Clinical epigenetics\| PubMed ID: 33536049	2021
Cell-free DNA methylation markers for differential diagnosis of hepatocellular carcinoma. BMC medicine\| PubMed ID: 35027051	2022

Chenyang Wang

Biography

JoVE Journal Publications

Other Publications